HeartSciences (HSCS) EBITDA (2021 - 2026)

HeartSciences (HSCS) has reported EBITDA for 6 consecutive years, with -$2.5 million the latest figure, recorded in Q2 2026.

• Quarterly EBITDA fell 32.08% year-over-year to -$2.5 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was -$8.4 million (down 0.62% YoY) and the FY2026 annual result came in at -$8.4 million, down 0.72% from the prior year.
• EBITDA eased to -$2.5 million in Q2 2026 per HSCS's latest filing, from -$2.1 million in the prior quarter.
• Over the last five years, EBITDA for HSCS reached as high as -$1.1 million in Q1 2022 and fell as low as -$2.5 million in Q2 2026.
• A 5-year average of -$1.8 million and a median of -$1.9 million in 2025 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2022 — EBITDA plunged 112.04% — and 2023, when it grew 19.17%.
• Year by year, EBITDA stood at -$1.8 million in 2022, then increased by 11.55% to -$1.6 million in 2023, then declined by 26.44% to -$2.0 million in 2024, then decreased by 4.45% to -$2.1 million in 2025, then slipped by 22.33% to -$2.5 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$2.5 million, -$2.1 million, and -$1.9 million for Q2 2026, Q4 2025, and Q3 2025 respectively.